AniClin Provides Pharmacokinetic Studies in Less than 5 Days
AniClin Preclinical Services (“AniClin”), specializing in in vivo services to support early drug development activities, is now offering complete pharmacokinetic (PK) studies in less than five days. This quick turnaround service comes after entering a strategic alliance with Taylor Technology, a subsidiary of PharmaNet Development Group, which specializes in supporting bioanalytical programs of any size from Discovery to Phase IV.
The PK package offers formulation, dosing, PK sampling, bioanalysis (plasma) of 6 timepoints, inclusive of quality control samples and front and back standard curves, all in less than 5 days. AniClin and Taylor Technology work seamlessly to meet this Fast PK timeline which involves the NCE arriving at AniClin where dosing is performed and plasma samples are collected. The samples are then delivered to Taylor Technology within two hours. The plasma samples are immediately processed upon receipt for development of non-GLP bioanalytical protocols, data analysis and estimation of PK parameters. The data and PK estimates are then emailed to the sponsor.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
